Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35
Catalyst Pharmaceuticals, Inc. -1.30%
Catalyst Pharmaceuticals, Inc. CPRX | 25.85 | -1.30% |
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:
CPRX) with a Buy and raises the price target from $33 to $35.
